Notably, inhibition of DYRK1A has been suggested as both a possible therapeutic to enhance cognition in people who have DS and as a possible AD therapeutic strategy (De la Torre et al., 2014; Yin et al., 2017; Neumann et al., 2018; Nguyen et al., 2018). Here, DYRK1A is linked to Dravet syndrome.